14.6 C
New York
Monday, September 25, 2023

HHS and the Steven & Alexandra Cohen Basis Announce $2M

The U.S. Division of Well being and Human Companies and the Steven & Alexandra Cohen Basis have introduced $2 million in Part 2 prizes for the LymeX Diagnostics Prize. By October 2023, the ten Part 1 winners are collaborating in a digital accelerator designed to assist them refine their ideas for detecting energetic Lyme illness infections in folks. In the course of the Part 2 accelerator, the cohort has entry to digital studying, mentorship, biorepository subject material experience, and networking alternatives. The purpose of this multiphase LymeX Innovation Accelerator (LymeX) competitors is to nurture the event of diagnostics towards Meals and Drug Administration evaluation.

Utilizing a prize competitors mannequin in keeping with the America COMPETES Act, the LymeX Diagnostics Prize incorporates money prizes alongside a spread of non-monetary sources to stimulate the market and produce collectively a various group of specialists. The necessity for brand spanking new testing strategies for Lyme illness is just rising. The 2-tier antibody testing system—initially developed in 1994 for illness surveillance, not as a stand-alone diagnostic take a look at—depends on the presence of antibodies and might solely be used precisely 4 to 6 weeks after sufferers turn into contaminated. Nevertheless, out there remedies are only when used early within the acute stage of the illness.

“Beneath the Biden-Harris Administration, HHS has made it a precedence to develop Individuals’ entry to well being care—and notably the correct diagnostics essential for well timed remedy interventions,” stated Assistant Secretary for Well being Admiral Rachel L. Levine, M.D. “By our LymeX Innovation Accelerator public-private partnership with the Steven & Alexandra Cohen Basis, we’re incentivizing innovators throughout academia and the non-public sector to come back collectively to enhance Lyme illness diagnostics.”

Part 2 will award the $2 million prize pool based mostly on the accelerator cohort’s interim and ultimate submissions. In June 2023, the ten Part 2 groups have been invited to submit idea papers to be thought-about for the interim prize. Based mostly on the judging panel’s evaluation, as much as ten groups could also be chosen to obtain an interim prize of as much as $75,000 every. On the finish of Part 2, as much as 5 groups could also be chosen to obtain an equal share of the remaining prize pool, with no less than $250,000 per winner.

“We’re proud to associate with HHS to offer the sources to advance these diagnostic ideas towards FDA evaluation,” stated Alex Cohen, President of the Steven & Alexandra Cohen Basis. “Creating checks for energetic Lyme an infection is a crucial first step towards enhancing outcomes for this disabling illness.”

In October 2023, the cohort will submit ultimate idea papers that element resolution refinement, embody medical and affected person enter, and suggest a roadmap from lab to market that features FDA evaluation. The competitors judging panel—composed of specialists in areas comparable to vector-borne illness biology, medical and know-how translation, affected person expertise and advocacy, and diagnostic science and know-how—will consider eligible submissions in accordance with official Part 2 analysis standards. Based mostly on the judges’ evaluations, the judging panel will advocate as much as 5 Part 2 winners of the LymeX Diagnostics Prize.

Due to a $10 million pledge to the LymeX Diagnostics Prize from the Steven & Alexandra Cohen Basis, a further $7 million in LymeX prizes are projected to be out there sooner or later. HHS plans to announce further particulars for the following stage of the LymeX Diagnostics Prize later this yr.

As well as, a choice of accelerator sources can be made out there to the general public on the competitors web site to help broader innovation in Lyme illness diagnostics and remedy.

About LymeX
The LymeX Diagnostics Prize is sponsored by the LymeX Innovation Accelerator, a partnership between the U.S. Division of Well being and Human Companies and the Steven & Alexandra Cohen Basis. LymeX is the world’s largest public-private partnership for Lyme illness, fostering collaborative innovation amongst sufferers and advocates, academia, nonprofits, business, and authorities. As a part of a bigger moonshot, LymeX is figuring out, creating, and implementing developments in Lyme illness care. Along with accelerating next-generation diagnostics, LymeX is spearheading growth of human-centered options and fostering breakthroughs in schooling and consciousness. For extra info, go to lyme-x.org.

Concerning the U.S. Division of Well being and Human Companies
HHS enhances and protects the well being and well-being of all Individuals. HHS fulfills that mission by offering for efficient well being and human providers and by fostering sound, sustained advances within the sciences underlying drugs, public well being, and social providers. For extra info, go to hhs.gov.

Concerning the Steven & Alexandra Cohen Basis
The Steven & Alexandra Cohen Basis is dedicated to inspiring philanthropy and group service by creating consciousness, providing steering, and main by instance to point out the world what giving can do. The Basis’s grants help nonprofit organizations based mostly in america that both assist folks in want or remedy complicated issues. The Basis is the biggest non-public funder of Lyme and tick-borne illness analysis in america with over $75 million disbursed for groundbreaking research in prevention, diagnostics, and remedy in addition to constructing important analysis infrastructure to catalyze innovation. The Basis additionally spearheads grassroots campaigns to encourage others to present. For extra info, go to steveandalex.org.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles